Conversion from tacrolimus to cyclosporine for a non-dose-dependent tacrolimus-induced toxicity, a pediatric kidney transplant recipient case report

Transplantation Proceedings

Volumn 36, Issue 5, 2004, Pages 1332-1335

  Ghio, L ^a   Ferraresso, M ^b,d   Giani, M ^a   Mihatsch, M ^c   Edefonti, A ^a  

^a PARKINSON INSTITUTE   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; INSULIN; METHYLPREDNISOLONE; PREDNISOLONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; CADAVER KIDNEY; CASE REPORT; CELL VACUOLE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIALYSIS; DIET RESTRICTION; DIETARY INTAKE; DOSE RESPONSE; ELECTRON MICROSCOPY; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; MICROEMULSION; NEPHROTOXICITY; NEUTROPHIL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW;

EID: 3142636619     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.05.039     Document Type: Article

References (14)

1. Shapiro R., Scantlebury V.P., Jordan M.L., et al. Pediatric transplantation under tacrolimus-based immunosuppression. Transplantation. 67:1999;299
2. Venkataramanan R., Swaminathan A., Prasad T., et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmakokinet. 29:1995;404
3. Racusen L.C., Solez K., Colin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 55:1999;713
4. Aperia A., Ibarra F., Svensson L.B., et al. Calcineurin mediates α-adrenergic stimulation of Na+, K+, -ATPase activity in renal tubule cells. Proc Natl Acad Sci USA. 89:1992;7394
5. Lang P., Baron C. Molecular mechanisms of immunosuppressive chemical agents recently introduced in clinical transplantation protocols. Nephrol Dial Transplant. 12:1997;2050
6. Kokado Y., Takahara S., Kyo M., et al. Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation. Transplant Proc. 31:1999;1151
7. Rostaing L., Tran-van T., Cisterne J.M., et al. Influence of FK506 trough levels on glomerular hemodynamics at 3 months in kidney transplant recipients. Transplant Proc. 30:1998;1282
8. Woodle E.S., Cronin D., Newell K., et al. Tacrolimus therapy for refractory allograft rejection definition of the histological response by protocol biopsies. Transplantation. 62:1996;906
9. Trimarchi H.M., Troung L.D., Brennan S., et al. FK506-associated thrombotic microangiopathy report of two cases and review of the literature. Transplantation. 67:1999;539
10. Randawa P.S., Saad R.S., Jordan M., et al. Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. Transplantation. 67:1999;85
11. Pirsh J.D., Miller J., Deierhoi M.H., et al. A Comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation FK506 kidney transplant study group. Transplantation. 63:1997;977
12. Greenspan L.C., Stephen E.G., Leung M.A., et al. Increased incidence in post-transplant diabetes mellitus in children a case control analysis. Pediatric Nephrol. 17:2002;1
13. Krentz A.J., Dmitrewski J., Mayer D., et al. Postoperative glucose metabolism in liver transplant recipients a two-year prospective randomized study of cyclosporine versus FK506. Transplantation. 57:1994;1666
14. Ellis D. Clinical use of tacrolimus (FK506) in infants and children with renal transplants. Pediatr Nephrol. 9:1995;487